Literature DB >> 25170527

Incorporation of (57)Fe-isotopically enriched in apoferritin: formation and characterization of isotopically enriched Fe nanoparticles for metabolic studies.

T Konz1, M Montes-Bayón, A Sanz-Medel.   

Abstract

The use of (57)Fe-isotopically enriched ferritin for the accurate measurement of Fe : ferritin ratios is proposed for metabolic studies. Thus, the synthesis of (57)Fe-isotopically enriched ferritin from horse apo-ferritin and isotopically enriched (NH4)2(57)Fe(II)(SO4)2 (Mohr's salt) is conducted. Size exclusion chromatography on-line with UV-VIS absorption (at 380 nm) is used in order to monitor the loading process of apo-ferritin. These studies revealed that the Fe-incorporation process involves also the formation of protein aggregates (oligomers) showing higher molecular mass than ferritin. A final optimized protocol involving incubation of the synthesized standard with guanidine hydrochloride (pH 3.5) has provided the best conditions for maintaining a stable protein structure without aggregates. Such (57)Fe-isotopically enriched ferritin was characterized and contained an average of 2200 atoms of Fe per mole of ferritin. The evaluation of the Fe-core after saturation with (57)Fe by Transmission Electron Microscopy (TEM) has revealed the formation of (57)Fe nanoparticles with a similar diameter to that of the commercial Fe-containing ferritin, confirming the process of Fe uptake, oxidation and mineralization within the protein cavity. The synthesized (57)Fe-ferritin shows great potential as a nanometabolic tracer to study the kinetics of Fe release in the cases of iron metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25170527     DOI: 10.1039/c4an01187b

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  1 in total

1.  Atomic resolution studies detect new biologic evidences on the Turin Shroud.

Authors:  Elvio Carlino; Liberato De Caro; Cinzia Giannini; Giulio Fanti
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.